The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

FDA grants Orphan Drug Designation to BI-1206 for patients with previously treated MCL

Feb 7, 2019

On 30 January 2019, BI-1206, a monoclonal antibody that selectively binds to CD32B in B cells, was granted Orphan Drug Designation by the U.S. Food and Drug Administration(FDA) for the treatment of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL).

The Orphan Drug Designation granted by the FDA occurs as BI-1206 is currently in a dose-escalation, consecutive-cohort, open-label phase I/IIa trial ( NCT03571568). This trial is evaluating BI-1206 in combination with rituximab in patients with R/R B cell non-Hodgkin lymphoma, including MCL, follicular lymphoma and marginal zone lymphoma.

According to the drug manufacturers, the Orphan Drug Designation granted to BI-1206 by the FDA could provide evidence “to support the use of BI-1206 in combination with rituximab”, which would provide a future treatment option for patients with MCL.

  1. PR Newswire. BioInvent receives FDA orphan designation for BI-1206 for mantle cell lymphoma. https://www.prnewswire.com/news-releases/bioinvent-receives-fda-orphan-designation-for-bi-1206-for-mantle-cell-lymphoma-300786542.html. [Accessed 2019 Feb 07]